MARKET

NUZTF

NUZTF

Neurizon Therapeutics
OTCMQB
0.070
NaN%
Closed 09:30 01/16 EST
OPEN
--
PREV CLOSE
0.070
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
0.100
52 WEEK LOW
0.070
MARKET CAP
58.06M
P/E (TTM)
-3.1818
1D
5D
1M
3M
1Y
5Y
1D
FDA CLEARS NUZ-001 FOR ENTRY INTO HEALEY ALS PLATFORM TRIAL
Reuters · 12/11/2025 20:50
FDA Clears Neurizon Therapeutics' NUZ-001 for HEALEY ALS Platform Trial
Reuters · 12/11/2025 20:50
Elanco Executive Justine Conway Appointed as Neurizon Therapeutics Board Observer
Reuters · 11/26/2025 23:17
Elanco in licensing pact with Australia’s Neurizon
Seeking Alpha · 07/03/2025 11:40
About NUZTF
Neurizon Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is engaged in advancing treatments for neurodegenerative diseases. It is developing its lead drug candidate, NUZ-001, for the treatment of Amyotrophic Lateral Sclerosis (ALS), which is the common form of motor neurone disease. ALS treatments for patients while exploring the potential of NUZ-001 for broader neurodegenerative applications. ALS is a devastating neurodegenerative condition that primarily affects nerve cells that control voluntary muscles. Through international collaborations and rigorous clinical programs, it is focused on creating new horizons for patients and families impacted by complex neural disorders.

Webull offers Neurizon Therapeutics Ltd stock information, including OTCMQB: NUZTF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NUZTF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NUZTF stock methods without spending real money on the virtual paper trading platform.